Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Journal of Clinical Oncology · 20.10.2024 · 42 (30) · 3581-3592
DOI: 10.1200/jco.23.02786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.10.2024. Verfasst von Michael D Jain und 31 weiteren Autor:innen. Beteiligte Einrichtung: Moffitt Cancer Center, Tampa, FL. Hauptthemen laut MEDLINE: Biological Products, Lymphoma, Large B-Cell, Diffuse, Immunotherapy, Adoptive, Antigens, CD19. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known about the long-term survivorship after CAR T-cell therapy. METHODS We previously reported the results of 298 patients who were leukapheresed with the intent to receive standard-of-care axi-cel (n = 275 infused) after two or more previous lines of therapy at a median follow-up of 12.9 months. Here, we report extended follow-up of this cohort to a median of 58 months, with a focus on late survivorship events. RESULTS Among axi-cel–infused patients, progression-free survival at 5 years was 29% and overall survival (OS) at 5 years was 40%. The 5-year lymphoma-specific survival was 53% with infrequent late relapses. However, the 5-year nonrelapse mortality (NRM) was 16.2%, with over half of NRM events occurring beyond 2 years. Patients who were 60 years and older had a lower risk of relapse ( P = .02), but a higher risk of NRM compared with patients younger than 60 years (NRM odds ratio, 4.5 [95% CI, 2.1 to 10.8]; P < .001). Late NRM was mainly due to infections and subsequent malignant neoplasms (SMNs). In total, SMNs occurred in 24 patients (9%), including therapy-related myeloid neoplasms (n = 15), solid tumors (n = 7), and unrelated lymphoid malignancies (n = 2). CONCLUSION In the standard-of-care setting, axi-cel exhibits outcomes consistent with those reported in clinical trials, with sustained, durable responses observed at the 5-year time point. However, late infections and the development of SMN are key survivorship issues that reduce long-term survival after CAR T-cell therapy, particularly in the elderly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Moffitt Cancer Center, Tampa, FL.
- University of Miami Miller School of Medicine, Miami, FL.
- The University of Texas MD Anderson Cancer Center, Houston, TX.
- Stanford University Medical Center, Stanford, CA.
- Washington University School of Medicine and Siteman Cancer Center, St Louis, MO.
- Mayo Clinic, Rochester, MN.
ORCID-Profile: Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Olalekan Oluwole, Joseph McGuirk, Abhinav Deol, Andre Goy, Javier Munoz, Matthew Ulrickson, Jason Westin, Julio C Chavez, Dilan Patel, Miriam T Jacobs, Radhika Bansal, N Nora Bennani, Aaron P Rapoport, Julie M Vose, David B Miklos, Sattva S Neelapu, Frederick L Locke, Saurabh Dahiya
Förderung
- NCI NIH HHS
Zitieren
APA
Jain, M. D., Spiegel, J. Y., Nastoupil, L. J., Tamaresis, J., Ghobadi, A., Lin, Y., Lekakis, L., Reagan, P., Oluwole, O., McGuirk, J., Deol, A., Dorritie, K. A., Sehgal, A. R., Goy, A., Hill, B. T., Andreadis, C., Munoz, J., Ulrickson, M., Westin, J., …, & Dahiya, S. (2024). Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology, 42(30), 3581-3592. https://doi.org/10.1200/jco.23.02786
Vancouver
Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, et al. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology. 2024;42(30):3581-3592. doi:10.1200/jco.23.02786
BibTeX
@article{Jain2024,
author = {Jain, Michael D and Spiegel, Jay Y and Nastoupil, Loretta J and Tamaresis, John and Ghobadi, Armin and Lin, Yi and Lekakis, Lazaros and Reagan, Patrick and Oluwole, Olalekan and McGuirk, Joseph and Deol, Abhinav and Dorritie, Kathleen A and Sehgal, Alison R and Goy, Andre and Hill, Brian T and Andreadis, Charalambos and Munoz, Javier and Ulrickson, Matthew and Westin, Jason and Chavez, Julio C and Patel, Dilan and Jacobs, Miriam T and Bansal, Radhika and Bennani, N Nora and Patel, Vivek G and Rapoport, Aaron P and Vose, Julie M and Miklos, David B and Neelapu, Sattva S and Locke, Frederick L and Lunning, Matthew and Dahiya, Saurabh},
title = {Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {30},
pages = {3581--3592},
doi = {10.1200/jco.23.02786}
}
EUVIMED